Goldman Sachs
CMPX icon

Goldman Sachs’s Compass Therapeutics CMPX Stock Holding History

Goldman Sachs’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.73M Buy
3,531,000
+1,535,606
+77% +$4.53M ﹤0.01% 3485
2026
Q1 		$10.6M Buy
1,995,394
+477,979
+31% +$2.76M ﹤0.01% 3030
2025
Q4 		$8.15M Buy
1,517,415
+477,744
+46% +$2.21M ﹤0.01% 3289
2025
Q3 		$3.64M Buy
1,039,671
+923,323
+794% +$2.92M ﹤0.01% 3938
2025
Q2 		$303K Sell
116,348
-117,174
-50% -$242K ﹤0.01% 5439
2025
Q1 		$444K Sell
233,522
-156,917
-40% -$417K ﹤0.01% 5255
2024
Q4 		$566K Buy
390,439
+19,310
+5% +$32.1K ﹤0.01% 5180
2024
Q3 		$683K Buy
371,129
+135,623
+58% +$169K ﹤0.01% 4880
2024
Q2 		$236K Buy
235,506
+112,794
+92% +$165K ﹤0.01% 5190
2024
Q1 		$243K Sell
122,712
-83,885
-41% -$145K ﹤0.01% 5049
2023
Q4 		$322K Sell
206,597
-13,585
-6% -$23.5K ﹤0.01% 4965
2023
Q3 		$434K Buy
220,182
+112,626
+105% +$278K ﹤0.01% 4713
2023
Q2 		$342K Sell
107,556
-90,966
-46% -$286K ﹤0.01% 4948
2023
Q1 		$649K Buy
+198,522
New +$779K ﹤0.01% 4679

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's CMPX Position: Q2 2026 in Review

Goldman Sachs increased its Compass Therapeutics (CMPX) stake by 77% in Q2 2026, buying an estimated $4.53M and bringing the position to 3,531,000 shares worth $7.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

Goldman Sachs first reported a position in CMPX in Q1 2023 and has held it in 14 quarters since. The position peaked at $10.6M in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Goldman Sachs held 3,531,000 shares of Compass Therapeutics worth $7.73M as of Q2 2026.
  • Goldman Sachs bought 1,535,606 Compass Therapeutics shares in Q2 2026, an estimated $4.53M.
  • Compass Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3485 holding.
  • Goldman Sachs first reported a position in Compass Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Goldman Sachs's Compass Therapeutics position peaked at $10.6M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.